On Aug. 4, 2020, Innovation Pharma reported receiving an update from a U.S. Regional Biocontainment Laboratory (RBL) based on ongoing in vitro testing supporting Brilacidin as a treatment for SARS-CoV-2, the novel coronavirus responsible for COVID-19.

A new experiment in a human lung epithelial cell line with the live (or wild type) virus showed that Brilacidin inhibited SARS-CoV-2 when administered post-infection. These results complement earlier RBL experiments in the same lung cell line that showed Brilacidin, when directly incubated with the live virus, exhibited potent inhibition.